The RITUXAN for RA EXPERIENCE Program

 

through Genentech
Rheumatology
Access Solutions

$4,000 per
12-month period
toward the cost of
Rituxan for eligible patients

Learn More

Indication

Rituxan® (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely- active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.

Rituxan is not recommended for treatment of patients with severe active infections.

Important Safety Information

RITUXAN administration can result in serious, including fatal, adverse reactions. These include: infusion reactions, tumor lysis syndrome (TLS), severe mucocutaneous reactions, and progressive multifocal leukoencephalopathy (PML).

Warnings and Precautions

Rituxan administration can also result in additional serious, including fatal, adverse reactions including:

  • hepatitis B reactivation
  • other infections including bacterial, fungal, new or reactivated viral infections
  • cardiovascular events

Patients should be closely observed for signs of infection if biologic agents and /or DMARDs other than methotrexate are used concomitantly

Common adverse reactions include infusion reactions and infections

For additional safety information, please see the full prescribing information, including BOXED WARNINGS and Medication Guide.

Attention Healthcare Provider: Provide Medication Guide to patient prior to RITUXAN infusion.

Print Page
 

Referrals for co-pay assistance

If privately or publicly insured patients have difficulty paying for their Rituxan for RA co-pay, co-insurance, or other expenses, Genentech Rheumatology Access Solutions can refer them to an independent, non-profit organization that supports RA

Patients who are referred for co-pay assistance need not be enrolled in Genentech Rheumatology Access Solutions and can simply call 1-866-681-3261 for a referral. Co-pay assistance may be available for patients who are privately or publicly insured, including Medicare and Medicaid patients.


  • Genentech and Biogen Idec do not influence or control the operations of these independent, nonprofit organizations (INOs), but Genentech Rheumatology Access Solutions can assist patients to navigate the process of seeking co-pay assistance by making a referral that is appropriate based on a patient’s diagnosis and by assisting with the application process.
  • We cannot guarantee co-pay assistance once a patient has been referred by Genentech Rheumatology Access Solutions. The INOs to which we refer patients each have their own criteria with regard to patient eligibility, including financial eligibility.